S861 Knowledge About Preventive Health Guidelines for Inflammatory Bowel Diseases in Patients: A Quality Improvement Project

Abstract

Colonic surface area for humans is ;3,000 greater than rat. Considering species-specific MC1R receptor sensitivity differences and other variables, such as GI transit time, pH, and proteolytic enzyme activity, a dose of 20 mg/day was estimated to be the best choice for observation of efficacy in the phase 2 trial. Conclusion: Collectively, these findings support further development of PL8177 as a treatment option for GI inflammatory diseases in humans. This will be further examined in the phase 2 trial in humans with UC.